Trexquant Investment LP Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Trexquant Investment LP grew its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 7.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,098 shares of the biotechnology company’s stock after buying an additional 8,553 shares during the period. Trexquant Investment LP owned approximately 0.20% of Blueprint Medicines worth $11,085,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP bought a new position in shares of Blueprint Medicines in the 3rd quarter valued at about $32,000. R Squared Ltd purchased a new position in shares of Blueprint Medicines in the 4th quarter worth approximately $51,000. Headlands Technologies LLC bought a new position in shares of Blueprint Medicines during the 4th quarter valued at approximately $65,000. Asset Management One Co. Ltd. bought a new position in shares of Blueprint Medicines during the 4th quarter valued at approximately $88,000. Finally, Van ECK Associates Corp lifted its position in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after buying an additional 363 shares during the last quarter.

Blueprint Medicines Price Performance

NASDAQ BPMC opened at $90.01 on Thursday. The company has a market cap of $5.75 billion, a PE ratio of -83.34 and a beta of 0.75. Blueprint Medicines Co. has a 52-week low of $80.68 and a 52-week high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm’s 50 day moving average price is $96.75 and its 200-day moving average price is $94.02.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Analysts Set New Price Targets

BPMC has been the topic of a number of analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Jefferies Financial Group started coverage on Blueprint Medicines in a research report on Monday, March 17th. They set a “buy” rating and a $135.00 target price for the company. Finally, Wolfe Research assumed coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.95.

Insider Activity at Blueprint Medicines

In related news, insider Ariel Hurley sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now owns 14,967 shares in the company, valued at $1,496,700. The trade was a 13.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,608 shares of company stock valued at $3,319,587 over the last quarter. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.